Jul 1, 2025 | Benefits preservation, Diabetes, GLP-1s, MedBen Rx, Ozempic, Rebates, Specialty Drugs, Spread Pricing, Transparency, Wegovy, Weight loss, Weight loss drugs
The 2025 Milliman Medical Index confirms what many employers are seeing firsthand: prescription drug costs are rising faster than any other health care expense, with a 9.7% increase over the past year. To help employers reclaim their drug spend, MedBen Rx offers a...
May 19, 2025 | Biosimilar, Cancer, Drug costs, Generic Drugs, GLP-1s, Rx Costs, Study
Prescription drug spending in the U.S. climbed 10.2% in 2024, reaching nearly $806 billion, according to a report from the American Society of Health-System Pharmacists. A significant portion of this growth is attributed to the rapid rise of...
Nov 21, 2024 | GLP-1s, MedBen Rx, Wegovy, Weight loss drugs, Zepbound
Bariatric surgeries to treat obesity dropped 25.6% from 2022 to 2023, while prescriptions for GLP-1 drugs more than doubled during that period, according to a new study of privately insured Americans with obesity. However, those who opt for the surgery are...
Sep 3, 2024 | Biosimilar, Drug costs, GLP-1s, Humira, Mounjaro, Ozempic, Rx Costs, Stelara, Trulicity, Wegovy
Humira continued to be the costliest prescription drug for self-funded health plans in 2023 by a comfortable margin, according to a recent Milliman commercial drug trends review. Used to treat a variety of conditions from Crohn’s to rheumatoid arthritis and psoriatic...
